3M's $12.5 billion settlement to address 'forever chemicals' in drinking water receives final court approval
By James Rogers
Payments are scheduled to begin in the third quarter of 2024, according to 3M
3M Co.'s previously announced $12.5 billion settlement agreement with U.S. public water suppliers has received final approval from a U.S. District Court in Charleston, S.C.
Last year 3M (MMM) improved the terms of the proposed settlement of $10.5 billion to $12.5 billion for the company's role in contaminated drinking water with per- and polyfluoroalkyl substances, also known as PFAS or "forever chemicals." The agreement, which is now finalized, will support public water suppliers that detect PFAS at any level or may do so in the future and will benefit U.S.-based public water suppliers that provide drinking water to Americans across the country, according to 3M.
"This is yet another important step forward for 3M as we continue to deliver on our priorities," 3M CEO Mike Roman said in a statement. "The final approval of this settlement and continued progress toward exiting all PFAS manufacturing by the end of 2025 will further our efforts to reduce risk and uncertainty as we move forward."
Related: 3M makes changes to improve terms of settlement of up to $12.5 billion for 'forever chemicals' in drinking water, NY AG says
As previously disclosed, the consumer, industrial and healthcare-products company has recorded an accrual of $10.3 billion related to the settlement, which reflects the pre-tax present value of the expected payments over 13 years. Payments are scheduled to begin in the third quarter of 2024, provided there are no pending appeals of the final approval order. "3M also continues to actively engage in insurance recovery activities," the company said in its statement.
3M has been dealing with other high-profile settlements. Last week the company said that its Combat Arms Earplug litigation is nearing its final resolution, with the company agreeing to pay up to $6 billion to settle all claims.
In a separate announcement Monday, the industrial giant completed the spinoff of its healthcare business. Solventum Corp. (SOLV.WI) is listed on the New York Stock Exchange. "Both companies are positioned to pursue their respective growth and tailored capital allocation plans, and I am excited to see both companies succeed as they innovate new solutions and create value for their respective stakeholders," Roman said in a statement.
Related: 3M to pay $6 billion as Combat Arms Earplug settlement nears final resolution
3M's board approved the spinoff last month. The company has retained 19.9% of the outstanding shares of Solventum's common stock, which will be monetized within five years following the spin-off.
3M shares rose 2.3% in premarket trades Monday. 3M's stock is down 18.9% in 2024, compared with the S&P 500 index's gain of 10.2%.
-James Rogers
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
04-01-24 0755ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing